会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • MANIFOLD FOR USE IN MEDICAMENT DISPENSER
    • 用于药物分配器的使用说明
    • US20100000529A1
    • 2010-01-07
    • US11722193
    • 2005-12-19
    • David PrimeRichard Ian Walker
    • David PrimeRichard Ian Walker
    • A61M15/00
    • A61M15/0045A61M15/0008A61M15/0041A61M15/0043A61M15/0051A61M15/0055A61M15/0071A61M16/127A61M2202/064A61M2206/16
    • There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The manifold is arranged such as to delay the emptying of the medicament powder from the blister pocket.
    • 提供了用于药物分配器装置中用于从泡罩包装的开放的泡罩口袋输送药物粉末的歧管。 歧管包括主体,主体限定具有烟囱入口的烟囱和用于将烟气从烟囱入口引导到烟囱出口的烟囱出口; 所述主体还限定具有室入口和室出口的室。 烟囱出口和所述室入口彼此并排地相互接合,使得当所述泡罩包装的所述开放泡罩袋定位在其附近时,所述气流可以经由开口泡罩口从烟囱出口引导到室入口以夹带 所述药物粉末并且能够在从所述室入口到所述室出口的气流中进行输送。 歧管布置成延迟药物粉末从泡罩袋中排空。
    • 5. 发明申请
    • MANIFOLD FOR USE IN MEDICAMENT DISPENSER
    • 用于药物分配器的使用说明
    • US20100000528A1
    • 2010-01-07
    • US11722188
    • 2005-12-19
    • Mark Gregory PalmerRichard Ian WalkerColin John Rouse
    • Mark Gregory PalmerRichard Ian WalkerColin John Rouse
    • A61M15/00
    • A61M15/0045A61M15/0008A61M15/0041A61M15/0043A61M15/0051A61M15/0055A61M15/0071A61M16/127A61M2202/064A61M2206/16
    • There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The chamber is arranged to promote break up of said entrained medicament powder by exposing the entrained medicament powder to one or more regions of differential force during its transport through the chamber.
    • 提供了用于药物分配器装置中用于从泡罩包装的开放的泡罩口袋输送药物粉末的歧管。 歧管包括主体,主体限定具有烟囱入口的烟囱和用于将烟气从烟囱入口引导到烟囱出口的烟囱出口; 所述主体还限定具有室入口和室出口的室。 烟囱出口和所述室入口彼此并排地相互接合,使得当所述泡罩包装的所述开放泡罩袋定位在其附近时,所述气流可以经由开口泡罩口从烟囱出口引导到室入口以夹带 所述药物粉末并且能够在从所述室入口到所述室出口的气流中进行输送。 所述腔室布置成通过在夹带的药物粉末通过腔室的运输期间将夹带的药物粉末暴露于一个或多个不同的力区域来促进所述夹带的药物粉末的分解。
    • 8. 发明授权
    • Use of human prostrate cell lines in prostate cancer treatment
    • 在前列腺癌治疗中使用人类前列腺细胞系
    • US06972128B1
    • 2005-12-06
    • US09857691
    • 1999-12-09
    • Angus George DalgleishPeter Michael SmithAndrew Derek SuttonAnthony Ian Walker
    • Angus George DalgleishPeter Michael SmithAndrew Derek SuttonAnthony Ian Walker
    • A61K9/08A61K35/48A61K38/00A61K39/00A61K39/02A61K39/04A61K39/05A61K39/08A61K39/10A61K39/39A61K47/10A61K47/20A61K47/42A61P13/08A61P35/00A61P37/04A61K35/12
    • A61K39/0011A61K2039/5152
    • The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and/or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only tumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50–300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.
    • 本发明涉及由用于治疗哺乳动物和人类癌症的同种异体免疫治疗剂的细胞系或细胞系的产品。 迄今为止,基于细胞的癌症疫苗的所有研究具有共同的特征,即意图使用含有至少一些与存在于患者肿瘤中的抗原共享的TSA和/或TAA的细胞。 在每种情况下,肿瘤细胞以起始点为前提,只有肿瘤细胞才含有相关的TSA或TAAs,并且细胞的组织起源与患者的肿瘤部位相匹配。 本发明的主要方面是使用永生化的正常非恶性细胞作为同种异体细胞癌疫苗的基础。 正常细胞不具有TSA或相关浓度的TAA,因此令人惊讶的是,正常细胞作为抗癌疫苗是有效的。 对于前列腺癌,例如,疫苗可以基于来源于前列腺的不同永生化正常细胞系的一种或组合。 使用50-300Gy的γ照射来致死细胞系,以确保它们在使用哺乳动物或人之前是无法复制的。